Literature DB >> 9568837

What is the most appropriate strategy to monitor functional iron deficiency in the dialysed patient on rhEPO therapy? Merits of percentage hypochromic red cells as a marker of functional iron deficiency.

I C Macdougall1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9568837     DOI： 10.1093/ndt/13.4.847

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  9 in total

Review 1.  The diagnostic plot: a concept for identifying different states of iron deficiency and monitoring the response to epoetin therapy.

Authors:  Christian Thomas; Andreas Kirschbaum; Dieter Boehm; Lothar Thomas
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

2.  Usefulness of Relative Hypochromia in Risk Stratification for Nonanemic Patients With Chronic Heart Failure.

Authors:  Muhammad Hammadah; Marie-Luise Brennan; Yuping Wu; Stanley L Hazen; W H Wilson Tang
Journal:  Am J Cardiol       Date:  2016-01-28       Impact factor: 2.778

3.  A study of the response of elderly patients with end-stage renal disease to epoetin alfa or beta.

Authors:  Johann C B Nicholas
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 4.  The role of iron supplementation during epoietin treatment for cancer-related anemia.

Authors:  M Hedenus; G Birgegård
Journal:  Med Oncol       Date:  2008-05-13       Impact factor: 3.064

5.  Erythrocyte and Reticulocyte Indices on the LH 750 as Potential Markers of Functional Iron Deficiency.

Authors:  Eloísa Urrechaga; Luís Borque; Jesús F Escanero
Journal:  Anemia       Date:  2010-06-16

6.  Serum or plasma ferritin concentration as an index of iron deficiency and overload.

Authors:  Maria Nieves Garcia-Casal; Sant-Rayn Pasricha; Ricardo X Martinez; Lucero Lopez-Perez; Juan Pablo Peña-Rosas
Journal:  Cochrane Database Syst Rev       Date:  2021-05-24

Review 7.  Biomarkers of hypochromia: the contemporary assessment of iron status and erythropoiesis.

Authors:  Eloísa Urrechaga; Luís Borque; Jesús F Escanero
Journal:  Biomed Res Int       Date:  2013-02-28       Impact factor: 3.411

8.  Managing anemia in lymphoma and multiple myeloma.

Authors:  Gunnar Birgegård
Journal:  Ther Clin Risk Manag       Date:  2008-04       Impact factor: 2.423

Review 9.  Application of Innovative Hemocytometric Parameters and Algorithms for Improvement of Microcytic Anemia Discrimination.

Authors:  Margreet Schoorl; Marianne Schoorl; Johannes van Pelt; Piet C M Bartels
Journal:  Hematol Rep       Date:  2015-06-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.